A framework for the definition and interpretation of the use of surrogate endpoints in interventional trials

Oriana Ciani(Bocconi University), Rod S Taylor(University of Southern Denmark), Martin Offringa(Hospital for Sick Children), Philippa Davies(University of Bristol), Sylwia Bujkiewicz(University of Leicester), Laura Richert(Université de Bordeaux), Robin Christensen(University of Copenhagen), Andrew Worrall, Vito Domenico Bruno(Istituto Clinico Sant'Ambrogio), Alain Amstutz(University Hospital of Basel), Alparslan Turan(Outcomes Research Consortium), Anthony Muchai Manyara(University of Bristol), Luca Bertolaccini(University of Milan), Joseph S. Ross(Yale University), Dalia Dawoud(Cairo University), Sarah Markham(King's College London), Christopher J. Weir(University of Edinburgh), Christina Danielli Coelho de Morais Faria(Universidade Federal de Minas Gerais), Yousef Rezaei(Iran University of Medical Sciences), An‐Wen Chan(World Health Organization), Mario Ouwens(AstraZeneca (Sweden)), Declan Devane(Ollscoil na Gaillimhe – University of Galway), Gary S. Collins(NIHR Birmingham Biomedical Research Centre), Jane Blazeby(University Hospitals Bristol NHS Foundation Trust), Falk Schwendicke(LMU Klinikum), Derek Stewart, Lucio Marinelli(Martin University), Nancy J. Butcher(University of Toronto), Peter B. Gilbert(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Amber Young(University of Bristol), Asbjørn Hróbjartsson(University of Southern Denmark), Ray Harris, Marissa Lassere(UNSW Sydney), John H. Powers(Leidos (United States)), Larisa G. Tereshchenko(Cleveland Clinic Lerner College of Medicine)
EClinicalMedicine
October 17, 2023
Cited by 60


Related Papers